PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Changes in Reimbursement Structure to Aid Greater Adoption of Brachytherapy - New analysis from Frost & Sullivan, U.S. Brachytherapy Markets, reveals that the market achieved revenue worth $157.6 million in 2004 and estimates to reach $300.2 million in 2010.
Changes in Reimbursement Structure to Aid Greater Adoption of Brachytherapy

 

NewswireToday - /newswire/ - San Antonio, TX, United States, 2005/04/20 - New analysis from Frost & Sullivan, U.S. Brachytherapy Markets, reveals that the market achieved revenue worth $157.6 million in 2004 and estimates to reach $300.2 million in 2010..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Traditionally, urologists are resistant to refer prostate cancer patients to radiation oncologists because they are either deterred by the technical complexity of brachytherapy procedures or prefer to perform prostatectomies due to their lucrative payments. However, reduced reimbursement for external beam and intensity modulated radiation therapy (IMRT) is likely to compel physicians to consider brachytherapy treatment options for their higher payments.

New analysis from Frost & Sullivan, U.S. Brachytherapy Markets, reveals that the market achieved revenue worth $157.6 million in 2004 and estimates to reach $300.2 million in 2010.

If you are interested in a virtual brochure, which provides manufacturers, end-users and other industry participants an overview of the latest analysis of the U.S. Brachytherapy Markets - then send an email to Danielle White - Corporate Communications at dwhite[.]frost.com with the following information: your full name, company name, title, telephone number, fax number, and email. Upon receipt of the above information, an overview will be sent to you via e-mail.

Centers for Medicare & Medicaid Services (CMS) have made many modifications to reimbursement payment structure for implantable seeds. The Medicare Prescription Drug, Improvement and Modernization Act of 2003 has also provided for separate payments for brachytherapy seeds.

“These policies eliminate restrictive monetary caps on brachytherapy seed reimbursement,” states Frost & Sullivan Research Analyst Sheila Ewing. “It enables physicians to decide the seed type, number of seeds, and advanced seed technologies, thereby reducing concern regarding reimbursement restrictions.”

While altering payment structure has helped stave off challenge from prostatectomies, alternative technologies such as hormone therapy or gene modification are posing new threats to brachytherapy. The market is also likely to be challenged by the slow growth in patient population.

Manufacturers promoting recently released positive long-term data results for seed implants can ease friction cased by these market restraints. Several favorable long-term studies on prostate and breast cancer therapies using brachytherapy and most of the results have been favorable. are opening the door for other cancer applications.

“More than 15 years of clinical trial results for brachytherapy drives acceptance in prostate cancer treatment,” observes Ewing. “However, limited data is available for usage of brachytherapy in the treatment of head, neck, and other cancers.”

The largest patient study of prostate brachytherapy primarily using Theragenics Corporation’s palladium seeds demonstrated a cancer-death rate of 81 percent. A 15-year clinical trial by Oncura, exclusively using its OncoSeed, results indicated after a five-year follow-up that 93 percent of patients remained cancer death. Meanwhile, Proxima Therapeutics, Inc.’s 3-year study using its MammoSite Radiation Therapy System (RTS) device for breast cancer, found no local recurrences.

These clinical trials open up markets with opportunities in new applications. Manufacturers that are ahead of their counterparts in providing positive clinical trials for additional cancer applications are anticipated to lead the market in revenue and shares.

“The studies provide critical evidence needed by physicians regarding the effectiveness of brachytherapy for treatment of prostate and breast cancer, and are expected to encourage brachytherapy procedures,” notes Ewing.

Greater opportunities for brachytherapy are expected, especially with the U.S. Congress’ resolution encouraging physicians to inform prostate cancer patients of all proven treatments available and use of prostate-specific antigen (PSA) and mammogram tests for early detection of cancer.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Changes in Reimbursement Structure to Aid Greater Adoption of Brachytherapy

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Danielle White - Frost.com 
210-247-2403
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Inferior Vena Cava Filters Market to Register a Strong Growth by 2025 Notes Persistence Market Research
Plasma Component Separator Market Set to Surge Significantly During 2017-2025 Says PMR
Persistence Market Research Releases Fertility Enhancing Treatment Market Snapshot by 2017-2025
Disposable Diabetes Devices Market Expected to Generate Huge Profits by 2025 Finds Reports Persistence Market Research
Cardiac Biomarkers Market Expected to Generate Huge Profits by 2017-2025 Reports PMR
Stone Management System Market Foreseen to Grow Exponentially Over 2017-2025 Finds PMR
Global Hemoglobinopathy Market Worth US$ 788M by 2024 According to Persistence Market Research
Dentsu Announces its Corporate Venture Capital Fund Dentsu Ventures Investment in Grail
Xenex Receives Top Honors from Frost & Sullivan for LightStrike™ - the Only Pulsed Xenon UV Disinfection System in the Healthcare Market
Partners HealthCare and GE Healthcare Launch 10-year Collaboration to Integrate Artificial Intelligence into Every Aspect of the Patient Journey
US Acute Care Solutions Celebrates 2-Year Anniversary
GE Healthcare Receives FDA Indication Approval for Visipaque™ (iodixanol) Injection for use with Coronary CT Angiography
Telehealth Vendors Expand mHealth Portfolio to Conquer New Growth Opportunities Finds Frost & Sullivan
GE Healthcare Acquires Asymptote for Complete, Digitally-enabled Cryogenic Cold Chain Technology Supporting Safe Manufacture And Delivery Of Cellular
ANVISA Approval for EMCM Facilitates the Progress of Leader Biomedical Operations in Brazil

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)